Coformulated quavonlimab and pembrolizumab (pembro) in combination with lenvatinib (lenva) as first-line (1L) therapy for patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 2 KEYSTEP-004 study.

被引：0
|
作者：
Rimassa, Lorenza
Li, Daneng
Ikeda, Masafumi
Yarchoan, Mark
Ryoo, Baek-Yeol
Kossler, Thibaud
Lim, Ho-Yeong
Kwiatkowski, Mariusz
Chang, Ting-Tsung
Kim, Jee Hyun
Casadei-Gardini, Andrea
Kudo, Masatoshi
Ren, Zhenggang
Calvo, Maria Varela
Llovet, Josep M.
Zhang, Yayan
Hatogai, Ken
Siegel, Abby B.
Cheng, Ann-Lii
机构：
[1] Humanitas Univ, IRCCS Humanitas Res Hosp Rozzano, Pieve Emanuele & Humanitas Canc Ctr, Dept Med Sci, Milan, Italy
[2] City Hope Natl Comprehens Canc Ctr, Duarte, CA USA
[3] Natl Canc Ctr Hosp East, Kashiwa, Japan
[4] Johns Hopkins Univ, Baltimore, MD USA
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[6] Geneva Univ Hosp, Geneva, Switzerland
[7] Samsung Med Ctr, Seoul, South Korea
[8] Szpital Wojewodzki Mikolaja Kopernika Koszalinie, Oddzial Dzienny Chemioterapii, Koszalin, Poland
[9] Natl Cheng Kung Univ Hosp, Tainan, Taiwan
[10] Seoul Natl Univ, Bundang Hosp, Coll Med, Seongnam, South Korea
[11] San Raffaele Res Hosp, Milan, Italy
[12] Kindai Univ, Fac Med, Osaka, Japan
[13] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[14] Hosp Univ Cent Asturias, Oviedo, Spain
[15] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Liver Dis, New York, NY USA
[16] Merck & Co Inc, Rahway, NJ USA
[17] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[18] Natl Taiwan Univ Hosp, Taipei, Taiwan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
283-424-425; 613-135-244-3829-325; 261-492-2769; 298-145-222-184-1022-9124; 613-3267-3650-6749; 613-615-646-2548-6283; 613-615-646-3281; 261-492-199-2823; 6; 5; 3; 2; 242; 28; 4; 1;
D O I：
10.1200/JCO.2024.42.3_suppl.484
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：484 / 484
页数：1
相关论文
共 50 条
  • [1] Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.
    Llovet, Josep M.
    Kudo, Masatoshi
    Cheng, Ann-Lii
    Finn, Richard S.
    Galle, Peter R.
    Kaneko, Shuichi
    Meyer, Tim
    Qin, Shukui
    Dutcus, Corina E.
    Chen, Erluo
    Dubrovsky, Leonid
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study.
    Loriot, Yohann
    Grivas, Petros
    De Wit, Ronald
    Balar, Arjun Vasant
    Siefker-Radtke, Arlene O.
    Zolnierek, Jakub
    Csoszi, Tibor
    Shin, Sang Joon
    Park, Se Hoon
    Atduev, Vagif
    Gumus, Mahmut
    Su, Yu-Li
    Karaca, Saziye Burcak
    Cutuli, Hernan
    Sendur, Mehmet Nahit
    Jia, Calvin
    O'Hara, Karen
    Franco, Sonia
    Matsubara, Nobuaki
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [3] Phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)
    El-Khoueiry, Anthony B.
    Kim, Richard D.
    Harris, William P.
    Sung, Max W.
    Waldschmidt, Dirk
    Iqbal, Syma
    Zhang, Xiaojing
    Nakajima, Keiko
    Galle, Peter R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [4] Phase 1b study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)
    Waldschmidt, D.
    El-Khoueir, A. B.
    Kim, R. D.
    Harris, W. P.
    Sung, M. W.
    Iqbal, S.
    Zhang, A.
    Nakajima, K.
    Galle, P. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 123 - 123
  • [5] Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
    Finn, R. S.
    Kudo, M.
    Merle, P.
    Meyer, T.
    Qin, S.
    Ikeda, M.
    Xu, R.
    Edeline, J.
    Ryoo, B-Y.
    Ren, Z.
    Cheng, A-L.
    Galle, P. R.
    Kaneko, S.
    Kumada, H.
    Wang, A.
    Mody, K.
    Dubrovsky, L.
    Siegel, A. B.
    Llovet, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1401 - S1401
  • [6] Updated results for pembrolizumab (pembro) monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC) in the phase II KEYNOTE-224 study
    van Laethem, J-L.
    Borbath, I.
    Karwal, M.
    Verslype, C.
    Van Vlierberghe, H.
    Kardosh, A.
    Zagonel, V.
    Stal, P.
    Sarker, D.
    Palmer, D.
    Vogel, A.
    Edeline, J.
    Cattan, S.
    Kudo, M.
    Cheng, A-L.
    Ogasawara, S.
    Siegel, A. B.
    Chisamore, M.
    Wang, A.
    Zhu, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S819 - S819
  • [7] PHASE 3 STUDY OF PEMBROLIZUMAB plus BELZUTIFAN plus LENVATINIB OR PEMBROLIZUMAB/QUAVONLIMAB plus LENVATINIB VERSUS PEMBROLIZUMAB plus LENVATINIB AS FIRST-LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA
    Choueiri, Toni
    Plimack, Elizabeth
    Powles, Thomas
    Voss, Martin
    Gurney, Howard
    Silverman, Rachel
    Perini, Rodolfo
    Rodriguez-Lopez, Karla
    Rini, Brian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A447 - A447
  • [8] A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Zhu, A. X.
    Finn, R. S.
    Mulcahy, M. F.
    Gurtler, J. S.
    Sun, W.
    Schwartz, J. D.
    Rojas, P.
    Dontabhaktuni, A.
    Youssoufian, H.
    Stuart, K. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Updated results of a phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)
    Galle, P. R.
    Kim, R. D.
    Sung, M. W.
    Harris, W. P.
    Waldschmidt, D.
    Cabrera, R.
    Mueller, U.
    Nakajima, K.
    Ishida, T.
    El-Khoueiry, A. B.
    ANNALS OF ONCOLOGY, 2020, 31 : S691 - S692
  • [10] Phase 3 study of first-line treatment with pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib for advanced renal cell carcinoma (RCC).
    Choueiri, Toni K.
    Plimack, Elizabeth R.
    Powles, Thomas
    Voss, Martin H.
    Gurney, Howard
    Silverman, Rachel Kloss
    Perini, Rodolfo F.
    Rodriguez-Lopez, Karla
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345